TY - JOUR
T1 - Development of a core outcome set for use in research evaluations of interventions for venous leg ulceration
T2 - International eDelphi consensus
AU - steering group listed here:
AU - Hallas, Sarah
AU - Nelson, E. Andrea
AU - O'Meara, Susan
AU - Gethin, Georgina
AU - Adderley, Una
AU - Meskell, Pauline
AU - Nixon, Jane
AU - O'Loughlin, Aonghus
AU - Probst, Sebastian
AU - Tawfick, Wael
AU - Wild, Thomas
N1 - Publisher Copyright:
© 2024 Tissue Viability Society / Society of Tissue Viability
PY - 2024/5
Y1 - 2024/5
N2 - Introduction: Venous leg ulceration (VLU) is a chronic, recurring condition with associated pain, malodour, impaired mobility and susceptibility to infection which in turn significantly impacts an individual's health-related quality of life. Randomised controlled trials (RCTs) aim to determine the efficacy of interventions to improve outcomes. To be useful, these outcomes should be consistently and fully reported across RCTs. A core outcome set (COS) is an agreed-upon standardised set of outcomes which should be, at a minimum, reported in all RCTs for a given indication including that of VLU. Aim: To gain consensus on which outcome domains and outcomes should be considered as core and therefore included in all RCTs of interventions in VLU treatment. Method: Two sequential, two round e-Delphi surveys were completed. The first gained consensus on core outcome domains and the second on core outcomes within those domains. Participants included: people with direct experience of having VLUs and their carers, healthcare professionals whose practice included VLU care and researchers within wound care (clinical, academic, industry). Results: Five outcome domains; healing, pain, quality of life, resource use and adverse events, and 11 outcomes were rated as core by participants. The patient and not the limb or ulcer was the preferred unit of analysis for reporting. Recommendations: We recommend investigators report on all five outcome domains, regardless of the type of intervention being evaluated. Future research is needed to identify measurement methods for the 11 identified outcomes. We also recommend investigators follow the CONSORT guidelines (http://www.consort-statement.org/).
AB - Introduction: Venous leg ulceration (VLU) is a chronic, recurring condition with associated pain, malodour, impaired mobility and susceptibility to infection which in turn significantly impacts an individual's health-related quality of life. Randomised controlled trials (RCTs) aim to determine the efficacy of interventions to improve outcomes. To be useful, these outcomes should be consistently and fully reported across RCTs. A core outcome set (COS) is an agreed-upon standardised set of outcomes which should be, at a minimum, reported in all RCTs for a given indication including that of VLU. Aim: To gain consensus on which outcome domains and outcomes should be considered as core and therefore included in all RCTs of interventions in VLU treatment. Method: Two sequential, two round e-Delphi surveys were completed. The first gained consensus on core outcome domains and the second on core outcomes within those domains. Participants included: people with direct experience of having VLUs and their carers, healthcare professionals whose practice included VLU care and researchers within wound care (clinical, academic, industry). Results: Five outcome domains; healing, pain, quality of life, resource use and adverse events, and 11 outcomes were rated as core by participants. The patient and not the limb or ulcer was the preferred unit of analysis for reporting. Recommendations: We recommend investigators report on all five outcome domains, regardless of the type of intervention being evaluated. Future research is needed to identify measurement methods for the 11 identified outcomes. We also recommend investigators follow the CONSORT guidelines (http://www.consort-statement.org/).
KW - Core outcome set
KW - Delphi
KW - Outcome domains
KW - Venous leg ulceration
KW - eDelphi
UR - http://www.scopus.com/inward/record.url?scp=85189790220&partnerID=8YFLogxK
U2 - 10.1016/j.jtv.2024.02.006
DO - 10.1016/j.jtv.2024.02.006
M3 - Article
AN - SCOPUS:85189790220
SN - 0965-206X
VL - 33
SP - 324
EP - 331
JO - Journal of Tissue Viability
JF - Journal of Tissue Viability
IS - 2
ER -